Alliancebernstein L.P. Purchases 43,638 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Alliancebernstein L.P. grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 623,156 shares of the biopharmaceutical company's stock after buying an additional 43,638 shares during the period. Alliancebernstein L.P. owned 0.57% of Regeneron Pharmaceuticals worth $443,893,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in REGN. State Street Corp raised its holdings in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock worth $5,153,603,000 after purchasing an additional 61,277 shares during the last quarter. Loomis Sayles & Co. L P raised its stake in shares of Regeneron Pharmaceuticals by 33.4% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock worth $1,122,168,000 after buying an additional 393,997 shares during the last quarter. Amundi lifted its holdings in Regeneron Pharmaceuticals by 45.8% in the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock valued at $1,138,074,000 after buying an additional 487,489 shares during the period. Norges Bank bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $802,036,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in Regeneron Pharmaceuticals by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company's stock worth $495,639,000 after acquiring an additional 22,538 shares during the period. Institutional investors own 83.31% of the company's stock.

Remove Ads

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded up $8.60 on Wednesday, hitting $625.60. 899,886 shares of the stock were exchanged, compared to its average volume of 679,610. The business's fifty day moving average is $680.43 and its 200 day moving average is $786.93. Regeneron Pharmaceuticals, Inc. has a 52 week low of $603.47 and a 52 week high of $1,211.20. The company has a market capitalization of $68.39 billion, a PE ratio of 16.34, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals's revenue was up 10.3% on a year-over-year basis. During the same period last year, the business posted $11.86 EPS. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's payout ratio is presently 2.30%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price target on the stock. UBS Group lowered Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a report on Monday. Finally, Robert W. Baird cut their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $966.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.